Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Variation in TRAF3IP2 and Methotrexate Response in Psoriasis and PsA
NCT07086924Recruiting
- Sponsor
- South Valley University
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of methotrexate in psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by South Valley University. Primary endpoint: Treatment of Psoriasis and Psoriatic arthritis at 3 months. Started Jun 2025; status: recruiting.
02
Drugs
methotrexate
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07086924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086924.